Vivian Chow
About Vivian Chow
Vivian Chow is the Sr. Manager of Partner Success at Dyno Therapeutics with extensive experience in managing strategic partnerships and technical operations within the gene therapy sector.
Company
Vivian Chow is currently employed at Dyno Therapeutics. As the Senior Manager of Partner Success, she plays a pivotal role in managing and nurturing partnerships that drive forward the company's gene therapy initiatives. Dyno Therapeutics focuses on using machine learning to develop next-generation adeno-associated virus (AAV) vectors for gene therapy.
Education and Expertise
Vivian Chow holds a Bachelor of Science (BS) degree in Biology from the Dominican University of California. Her educational background in biology provides a strong foundation for her extensive career in the biotechnology and pharmaceutical sectors. This academic experience supports her technical expertise, particularly in areas such as clinical bioanalytics, clinical manufacturing, and gene therapy operations.
Background
Vivian Chow has accumulated a wealth of experience in various roles within the biotechnology and pharmaceutical industry. She has held significant positions at Astellas Gene Therapies, Ultragenyx Pharmaceutical Inc., Monogram Biosciences, and BioMarin Pharmaceutical Inc. Her roles have spanned project management, clinical bioanalytics, and clinical manufacturing, showcasing her versatility and depth of experience in these fields.
Professional Journey
Vivian Chow's professional journey began at BioMarin Pharmaceutical Inc. where she worked as a Clinical Manufacturing Associate for three years. She then moved to Monogram Biosciences as a Clinical Lab Coordinator, followed by a role at Ultragenyx Pharmaceutical Inc. as a Project Specialist in Clinical Bioanalytics. Her career progressed at Astellas Gene Therapies where she held multiple roles including Project Manager, Alliance Manager, and finally as Senior Manager for Strategic Partnerships in Research & Technical Operations, before joining Dyno Therapeutics.